Hypertension, aortic stenosis, and aortic regurgitation

Aronow, Wilbert S.

doi:10.21037/atm.2017.11.30

Cited by 7 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We analyzed the three attributable risk factors (lead exposure, high SBP, and diet high in sodium) available in GBD 2019 of CAVD. We found out that high SBP remained the predominating attributable risk factor to CAVD, which is consistent with previous studies ( 20 , 30 , 31 ). The CANHEART Aortic Stenosis study, a large observational cohort study of 1.12 million individuals older than 65 years, using a population-based longitudinal approach revealed an independent and dose-response association between well-known cardiovascular risk factors such as hypertension, diabetes, as well as dyslipidemia and the risk of developing severe AS ( 20 ).…”

Section: Discussionsupporting

confidence: 93%

Global burden of calcific aortic valve disease and attributable risk factors from 1990 to 2019

Wang

Bao

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCalcific aortic valve disease (CAVD) was highly prevalent among developed countries and caused numerous deaths. Based on the Global Burden of Disease 2019, this study was designed to present comprehensive epidemiological information, attributable risks, and relevant factors.MethodsAll data were available online via the Global Health Data Exchange (GHDx). In this study, we analyzed the global incidence, prevalence, deaths, and disability-adjusted life years (DALYs) of CAVD across different regions from 1990 to 2019. We applied the estimated annual percentage changes (EAPCs) to evaluate the change trends and their attributable risks. In addition, we explored several relevant factors.ResultsFrom 1990 to 2019, the incidence cases, prevalence cases, CAVD-related deaths, and DALYs of CAVD gradually increased globally. However, the age-standardized death rate (ASDR) was relatively stable, and the age-standardized DALYs rate gradually declined during the past 30 years. Males and elderly individuals were more likely to suffer from CAVD. High systolic blood pressure (SBP) was the predominant attributable risk of disease burden that presented a global downward trend (death: EAPC = −0.68, 95% CI −0.77~−0.59, P < 0.001; DALYs: EAPC = −0.99, 95% CI −1.09 to −0.89, P < 0.001). Alcohol consumption (R = 0.79, P < 0.001), smoking prevalence (R = 0.75, P < 0.001), and calcium (R = 0.72, P < 0.001) showed a positive correlation with the age-standardized incidence rate (ASIR), whereas classic monsoon region (R = −0.68, P < 0.001) and mean temperature (R = −0.7, P < 0.001) showed a negative correlation with age-standardized incidence rate (ASIR). Besides, medical and healthcare resources presented a positive correlation with ASIR. Meanwhile, similar relationships were found in age-standardized prevalence rate (ASPR), ASDR, and age-standardized DALY rate (ASDALYR).ConclusionCAVD displays widely varied spatial distribution around the world, of which high SDI regions have the highest burdens. Age is a powerful factor and hypertension a predominant attributable risk factor. Moreover, controlling blood pressure, avoiding smoking, reducing alcohol consumption, and so on, could effectively reduce the burden of CAVD.

show abstract

Section: Discussionsupporting

confidence: 93%

Global burden of calcific aortic valve disease and attributable risk factors from 1990 to 2019

Wang

Bao

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Previous study reported that LVH was associated with severity of calcification of aortic valve, aortic stenosis and aortic regurgitation independent of HT, 11,14 therefore we asked if the same observation is found in our study population. Among the HT LVH+, 36 (32.6%) presented with calcified aortic valve and seven had aortic valve sclerosis, majority of them fell at the age group between 60 – 69 years old ( Additional File 4 ).…”

Section: Resultssupporting

confidence: 65%

Association of Socioeconomic Disparities and Predisposing Factors with Higher Prevalence of Hypertension related Left Ventricular Hypertrophy in Males: a Malaysian Community-Based Study

Jusoh

Rahman

Nasir

et al. 2022

Preprint

View full text Add to dashboard Cite

Left Ventricular Hypertrophy (LVH) is a risk for various cardiovascular events among those with hypertension (HT). However the prevalence of hypertension-related LVH (HT LVH+) in communities with lower socioeconomic status (SES) is not adequately reported. This study investigated the prevalence of HT LVH+ among the urban and rural males and the attributing factors. A total of 1,923 males who had echocardiographic examinations done were recruited. Their blood pressure was measured to diagnose those with or without hypertension. Left ventricular mass index was determined. Univariate analysis was performed to identify associated factors predisposing to LVH. A total of 992 males had HT, of which 264 had LVH, and were more prevalent in older age groups and Malays (p<0.001). Individuals from rural areas, with low income and low educational background were associated with higher LVH prevalence (p<0.001). Those with moderate aortic regurgitation was 3.17-fold higher in LVH. Ninety-nine normotensives had LVH, 71.7% came from rural. Total cholesterol and low density lipoprotein cholesterol levels were significantly higher in HT LVH+ from urban than the rural areas (p=0.029 and p=0.002, respectively). A quarter of the HT population in Malaysia develop LVH, majority of them were from rural, indicating that socioeconomic disparities contribute to the higher risk of HT LVH+. The rural populations may have attributed to different risk factors as opposed to those from urban, hence emphasize the need to deliver targeted strategies for prevention and management HT LVH+ by different SES.

show abstract

“…Hypertension is a risk factor for AS and associated with increased rate of progression and reduced survival 28 . It increases LV afterload and thereby LV mass, which is independently associated with mortality—15 g/m 2 increase is associated with a 61% increase in the risk of cardiovascular death.…”

Section: Aortic Stenosismentioning

confidence: 99%

“…Similarly, ramipril 10 mg/day was used to effectively reduce blood pressure and LV mass at 12 months in patients with moderate‐severe asymptomatic AS compared to placebo 32 . Further studies also suggest a protective effect of angiotensin‐converting enzyme (ACE) inhibition and angiotensin receptor blockers (ARBs), which reduce progression of aortic valve calcification, all‐cause mortality (−24%) and cardiovascular events (−23%) 28 …”

Section: Aortic Stenosismentioning

confidence: 99%

The advantages, pitfalls and limitations of guideline‐directed medical therapy in patients with valvular heart disease

Gill

Chehab

Allen

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

Heart failure is an inevitable end‐stage consequence of significant valvular heart disease (VHD) that is left untreated and increasingly encountered in an ageing society. Recent advances in transcatheter procedures and improved outcomes after valve surgery mean that intervention can (and should) be considered in all patients – even the elderly and those with multiple comorbidities ‐ at earlier stages of the natural history of primary VHD, before the onset of irreversible left ventricular dysfunction (and frequently before the onset of symptoms). All patients with known VHD should be monitored carefully in the setting of a heart valve clinic and those who meet guideline criteria for surgical or transcatheter intervention referred for intervention without delay. High quality evidence for the use of medical therapy in VHD is limited and achieving target doses in an elderly and comorbid population frequently challenging. Furthermore, determining whether the valve or ventricle is the principal disease driver is crucial (although the distinction is not always binary, and often unclear). Guideline‐directed medical therapy remains the mainstay of treatment for secondary mitral regurgitation ‐ although up to 50% of patients may fail to respond and should be considered for cardiac resynchronization, transcatheter or surgical valve intervention. Early and definitive management strategies are essential and should be overseen by a specialist Heart Team that includes a Heart Failure specialist. In this article, we provide an evidence‐based summary of approaches to the medical treatment of VHD and clinical guidance for the best management of patients in situations where high quality evidence is lacking.

show abstract

Hypertension, aortic stenosis, and aortic regurgitation

Cited by 7 publications

References 26 publications

Global burden of calcific aortic valve disease and attributable risk factors from 1990 to 2019

Global burden of calcific aortic valve disease and attributable risk factors from 1990 to 2019

Association of Socioeconomic Disparities and Predisposing Factors with Higher Prevalence of Hypertension related Left Ventricular Hypertrophy in Males: a Malaysian Community-Based Study

The advantages, pitfalls and limitations of guideline‐directed medical therapy in patients with valvular heart disease

Contact Info

Product

Resources

About